Abstract: New subunit vaccines from Haemophilus somnus are disclosed. The vaccines include an outer membrane protein extract of H. somnus which is enriched with iron-regulated proteins. Additional antigens, such as antigens derived from Pasteurella haemolytica, can be included in the vaccine composition to provide protection against a variety of disease states.

Abstract: A chimaeric protein, suitable for incorporation in a vaccine and capable of forming parts of a capsid assembly, comprises the amino acid sequence of the coat protein of phage MS-2, or a conservatively modified variant thereof, or sufficient of said sequence or variant to retain capsid-forming capability, which amino acid sequence has been modified by insertion of a foreign epitope in the region corresponding to a protuberant protein hairpin in the capsid assembly as shown in the crystal structure of the intact phage.

Abstract: A substantially purified antigen derived from a first species of parasitic nematodes, which antigen is capable of providing protection to a host from parasitism by a second nematode species, which may be the same as or different from the first nematode species, following vaccination of the host with the antigen, characterized in that the antigen is proteinaceous, has a pI between 3.8 and 4.4, can be bound by lentil lectin and Helix promatia lectin and has a molecular weight of approximately 45 kD as determined by SDS-PAGE.

Abstract: A cloned DNA fragment of Bordetella pertussis including the gene which codes for the pilinic subunit fim3, vectors which contain it and microorganisms transformed by the vectors.The protein and peptides corresponding to at least one epitope of the gene which codes for the pilinic subunit fim3 are particularly useful for the development of acellular anti-pertussis vaccines.In addition, a strain of Bordetella modified by a recombinant replication or genome-integration vector containing the cloned DNA fragment or the gene or a fraction thereof is particularly suitable for the development of a cellular anti-pertussis vaccine.

Abstract: B fraction of Borrelia burgdorferi, methods for preparing the B fraction, and compositions containing the B fraction, are disclosed and claimed.

Abstract: The invention relates to a vaccine which comprises an antigen and a lymphoid organ modifying agent. Suitable lymphoid organ modifying agents include 1,25-dihydroxy Vitamin D.sub.3, biologically active Vitamin D.sub.3 derivatives which are capable of activating the intracellular Vitamin D.sub.3 receptor, all trans-retinoic acid, retinoic acid derivatives, retinol, retinol derivatives and glucocorticoid. The vaccine composition may further comprise an immune response augmenting agent which enhances T cell lymphokine production. Suitable immune response augmenting agents include dehydroepiandrosterone (DHEA) and DHEA-derivatives. Examples of DHEA derivatives include DHEA-sulfate (DHEA-S), 16-.alpha.-bromo-DHEA, 7-oxo-DHEA, 16-.alpha.-Br-DHEA-S and 7-oxo-DHEA-S.

Abstract: What is described is a recombinant poxvirus, such as vaccinia virus, fowlpox virus and canarypox virus, containing foreign DNA from flavivirus, such as Japanese encephalitis virus, yellow fever virus and Dengue virus. In a preferred embodiment, the recombinant poxvirus generates an extracellular particle containing flavivirus E and M proteins capable of inducing neutralizing antibodies, hemagglutination-inhibiting antibodies and protective immunity against flavivirus infection. What is also described is a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal inoculated with the vaccine.

Abstract: Antigenic proteins may be expressed in bacteria by use of vectors having inserted therein DNA fragments from an envelope gene. The DNA fragments employed in the example are coding sequences found in the HTLV-I envelope gene. The bacteria used was E. coli. The antigenic proteins are useful in identifying antibodies to the organisms from which the DNA fragments were originally obtained.

Abstract: A method for treating a papilloma virus infection comprising topically administering hypericin which is effective to inhibit the replication, growth and/or the infectivity of the virus. The papilloma viruses include those capable of causing benign warts or a malignancy such as human papilloma virus-1 (HPV-1), HPV-2, HPV-6, HPV-11, HPV-16 and HPV-18.

Abstract: Murine monoclonal antibodies directed against a novel outer membrane protein (OMP) of Haemophilus influenzae have been isolated and characterized. The gene encoding of the outer membrane protein has also been isolated and characterized. Portions of the DNA sequence of the 15 kD OMP gene are useful as probes to diagnose the presence of Haemophilus influenzae in samples. These DNA's also make available polypeptide sequences of immunoreactive epitopes encoded within the gene, thus permitting the production of polypeptides which are useful as standards or reagents in diagnostic tests and/or as components of vaccines. Monoclonal antibodies directed against epitopes of the 15 kD OMP are also useful for diagnostic tests and as therapeutic agents for passive immunization.

Abstract: Method for the production of a subunit vaccine against porcine parvovirus (PPV). The method is comprised of a first step wherein a recombinant protein VP2 of PPV is obtained by using the replication of a recombinant baculovirus wherein the gene corresponding to VP2 has been previously inserted in cells of a permissive host. The protein VP2 obtained in this invention has the capacity of forming empty chimeric capsids with high immunogenicity and can be provided as a vaccine formulation for protecting pigs against PPV infection. The recombinant baculovirus AcMNPV.pPPVEx8 expresses the VP2 of PPV in conditions making possible the formation of pseudo-viral capsids.

Abstract: Novel attenuated strains of Aeromonas salmonicida are disclosed that are effective as live effective vaccines against furunculosis in fish. These vaccines may be administered by the immersion of fish in a solution of the vaccine. Methods of producing these strains and other strains having the identifying characteristics of these strains are also disclosed.

Abstract: This invention provides a method of reducing the output of Eimeria oocysts from a newborn chick which comprises administering to a laying hen at a suitable time prior to the hen laying a fertilized egg an amount of native or recombinant antigenic protein present in gametocytes of the Eimeria spp. effective to induce in the hen an immune response conferring protection via maternal immunity against infection or transmission by the Eimeria spp. in the offspring chick.

Abstract: A peptide having a sequence corresponding to a C-terminal portion of the Pseudomonas aeruginosa pilin protein is disclosed. The peptide is cross-reactive with surface peptides present in certain bacterial and fungal microorganisms, and is effective in inhibiting binding of such organisms to target epithelial cells. The peptide may also be employed in a vaccine composition, for producing immunity against such cross-reactive microorganisms. Also disclosed are methods of preparing peptides which are cross-reactive with the P. aeruginosa pilin peptide, and chimeric monoclonal antibodies immunoreactive with the pilin peptide.

Abstract: What is described is a modified vector, such as a recombinant poxvirus, particularly recombinant vaccinia virus, having enhanced safety. The modified recombinant virus has nonessential virus-encoded genetic functions inactivated therein so that virus has attenuated virulence. In one embodiment, the genetic functions are inactivated by deleting an open reading frame encoding a virulence factor. In another embodiment, the genetic functions are inactivated by insertional inactivation of an open reading frame encoding a virulence factor. What is also described is a vaccine containing the modified recombinant virus having nonessential virus-encoded genetic functions inactivated therein so that the vaccine has an increased level of safety compared to known recombinant virus vaccines.

Abstract: A breast cancer vaccine which comprises a mixture of tumor associated antigens (TAA) with low doses of recombinant interleukin-2 (IL-2) and granulocyte-macrophage colony stimulating factor (GM-CSF).

Abstract: New proteins and subunit antigens from P. haemolytica for use in stimulating immunity against respiratory diseases such as pneumonia, including shipping fever pneumonia, are disclosed. The subunit antigens include immunogenic amino acid sequences of P. haemolytica fimbrial protein, P. haemolytica plasmin receptor protein, and P. haemolytica 50K outer membrane protein and P. haemolytica leukotoxin. The antigens can be used in a vaccine composition, either alone or in combination. Also disclosed are methods of vaccination as well as methods of making the subunit antigens employed in the vaccines.

Abstract: An antigenic composition includes antigens obtainable from Campylobacter jejuni and may be used as a vaccine to induce protective antibodies against both Campylobacter coli and Campylobacter jejuni. The antigenic composition, and antisera specific to the antigens can be used to detect Campylobacter coli or Campylobacter jejuni infection. Diagnostic detection kits include the novel antigenic composition or antisera thereto.

Abstract: This invention provides a vaccine for the immunization of a vertebrate or invertebrate comprising an avirulent derivative of S. choleraesuis. The derivatives being substantially incapable of producing functional adenylate cyclase and/or cyclic AMP receptor protein. The invention also provides a vaccine for the immunization of a vertebrate and invertebrate comprising a virulent derivative of a pathogenic microbe said derivative being substantially incapable of producing functional adenylate cyclase and/or cyclic AMP receptor protein while being capable of expressing a recombinant gene derived from a pathogen of said vertebrate to produce an antigen capable of inducing an immune response in said vertebrate against said pathogen.

Abstract: The invention described includes methods and compositions useful in preventing infection by Pseudomonas aeruginosa and related organisms. Diclosed is a peptide having the sequence corresponding to an antigenic site in the protein exoenzyme S which is antigenically similar to a C-terminal portion of the Pseudomonas aeruginosa pilin protein. The peptide is cross-reactive with surface peptides present in certain bacterial and fungal microorganisms, and is effective in inhibiting binding of such organisms to target epithelial cells. The peptide may also be employed in a vaccine composition, for producing immunity against Pseudomonas aeruginosa as well as against such cross-reactive microorganisms.